Inovio Biomedical to Present at American Society of Gene Therapy Meeting
News May 31, 2007
Inovio Biomedical Corporation has announced that the company will make multiple presentations regarding its electroporation-mediated DNA delivery technology at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) being held in Seattle, WA, May 30 - June 3 at the Washington State Trade and Convention Center.
Inovio's DNA delivery systems are designed to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.
Three of the five poster presentations discuss pre-clinical studies that evaluated immune responses to DNA vaccines directed against major infectious diseases including malaria, HIV and hepatitis C.
In all cases Inovio's electroporation technology enhanced antibody and cellular immune responses when compared with traditional vaccine delivery methods. Two other Inovio presentations report innovations in the development of electroporation DNA delivery devices.
These presentations include: Immunogenicity of a Cytokine Enhanced Multi-Antigen pDNA Vaccine with and without In Vivo Electroporation in Rhesus Macaques.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.